News|Articles|October 23, 2020

Dangerous CV Drug-Drug Interactions: A 5-question Quiz

Cardiovascular medications are widely-prescribed in the US. Alex Evans, PharmD, MBA, drafted questions on the top 5 dangerous interactions he sees regularly in practice.

Medications for cardiovascular disease dominate the list of most widely-prescribed drugs in the US, and there's no doubt you probably prescribe them nearly every day in your practice. However, lurking behind some of those therapies are dangerous drug interactions. This quiz covers the top 5 interactions I see regularly in my practice as a community pharmacist.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Latest CME

Multimedia

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Zofia Piotrowska, MD, MHS; Helen H. Moon, MD

Dangerous CV Drug-Drug Interactions: A 5-question Quiz

Newsletter

Related Content

Sebela Submits NDA for Tegoprazan for GERD, Seeking Approval for NERD and Erosive Esophagitis

Population-Based eGFR Percentiles Linked to Kidney Failure and Mortality Risk, Study Finds

Chronic Pain Linked to Greater Risk of Hypertension: Daily Dose

Weekly Dose Podcast: Needle-Free Epinephrine, Pediatric Atopic Dermatitis Gains, Smarter Dementia Screening, Teen Depression Treatment, and Oral PCSK9 Data

Adjunctive Lumateperone Nearly Doubles Remission Rates at 6 Weeks in Adults With Major Depressive Disorder

Latest CME

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Real Psychiatry 2026

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

10th Annual School of Gastrointestinal Oncology

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Expert Illustrations and Commentaries™: Managing Hyperphosphatemia in CKD—A Closer Look at the Paracellular Pathway

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Cases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH)

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria

SimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Establishing the Rationale for ADC and ICI Combinations in TNBC

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

2026 International Symposium of Gastrointestinal Oncology (ISGIO)

26th Annual International Lung Cancer Congress

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

24th Annual School of Breast Oncology

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

ISGIO 2025: Advanced-Stage Colorectal Cancer

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

4th Annual International Congress on Pediatric Oncology

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies

Optimizing Multidisciplinary Care in TGCT

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Optimal Management of Complications of Sickle Cell Disease